pioglitazone has been researched along with Carcinoma, Epidermoid in 7 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment significantly reduced squamous lesions and the presence of airway basal cells, along with increasing normal epithelial cells in the airways of NTCU-exposed mice." | 1.72 | PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model. ( Alavi, K; Dwyer-Nield, LD; Ghosh, M; Hudish, LI; Hudish, TM; Keith, RL; McArthur, DG; Merrick, DT; Mirita, C; Smith, AJ; Sompel, K; Tennis, MA, 2022) |
| "Using a mouse model of lung squamous cell carcinoma (SCC), we performed transcriptome sequencing (RNA-Seq) to profile bronchial airway gene expression and found activation of the PI3K and Myc signaling networks in cytologically normal bronchial airway epithelial cells of mice with preneopastic lung SCC lesions, which was reversed by treatment with the PI3K Inhibitor XL-147 and pioglitazone, respectively." | 1.46 | Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. ( Lubet, RA; Miller, MS; Pan, J; Szabo, E; Wang, Y; Xiong, D; You, M; Zhang, Q, 2017) |
| "Oral squamous cell carcinomas (OSCC) were induced in male F344 rats by 4-nitroquinoline-1-oxide (NQO; 20 ppm in the drinking water for 10 weeks)." | 1.42 | Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ. ( Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Peng, X; Steele, VE, 2015) |
| "When pioglitazone was administered beginning 8 weeks after the first carcinogen treatment when microscopic adenomas already existed, pioglitazone significantly inhibited tumor load (sum of tumor volume per lung in average) by 64% (P < 0." | 1.36 | Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. ( James, M; Lu, Y; Lubet, RA; Szabo, E; Wang, Y; Wen, W; You, M, 2010) |
| "Pioglitazone treatment alone did not change the kinase activity of EGF receptors." | 1.29 | Pioglitazone attenuates the inhibitory effect of phorbol ester on epidermal growth factor receptor autophosphorylation and tyrosine kinase activity. ( Imamura, T; Kobayashi, M; Morioka, H; Sawa, T; Takada, Y; Takata, Y; Yang, GH, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dwyer-Nield, LD | 1 |
| McArthur, DG | 1 |
| Hudish, TM | 1 |
| Hudish, LI | 1 |
| Mirita, C | 1 |
| Sompel, K | 1 |
| Smith, AJ | 1 |
| Alavi, K | 1 |
| Ghosh, M | 1 |
| Merrick, DT | 1 |
| Tennis, MA | 1 |
| Keith, RL | 1 |
| McCormick, DL | 1 |
| Horn, TL | 1 |
| Johnson, WD | 1 |
| Peng, X | 1 |
| Lubet, RA | 3 |
| Steele, VE | 1 |
| Handley, N | 1 |
| Eide, J | 1 |
| Taylor, R | 1 |
| Wuertz, B | 1 |
| Gaffney, P | 1 |
| Ondrey, F | 1 |
| Xiong, D | 1 |
| Pan, J | 1 |
| Zhang, Q | 1 |
| Szabo, E | 2 |
| Miller, MS | 1 |
| You, M | 2 |
| Wang, Y | 2 |
| James, M | 1 |
| Wen, W | 1 |
| Lu, Y | 1 |
| Nakashiro, K | 1 |
| Begum, NM | 1 |
| Uchida, D | 1 |
| Kawamata, H | 1 |
| Shintani, S | 1 |
| Sato, M | 1 |
| Hamakawa, H | 1 |
| Takata, Y | 1 |
| Imamura, T | 1 |
| Yang, GH | 1 |
| Takada, Y | 1 |
| Sawa, T | 1 |
| Morioka, H | 1 |
| Kobayashi, M | 1 |
7 other studies available for pioglitazone and Carcinoma, Epidermoid
| Article | Year |
|---|---|
PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Desmoglein 3; Epithelial-Mesenchy | 2022 |
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Male; Mouth Neop | 2015 |
PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genomic | 2017 |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Topics: Animals; Biomarkers, Tumor; Bronchi; Carcinoma, Squamous Cell; Chemokines, CXC; Chemoprevention; Dis | 2017 |
Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Chemopreventi | 2010 |
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Chromans; DNA Mutational Analysis; Humans; Mouth Neoplas | 2003 |
Pioglitazone attenuates the inhibitory effect of phorbol ester on epidermal growth factor receptor autophosphorylation and tyrosine kinase activity.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Humans; Hypoglycemic Agents; Phosphorylation; Pioglitazone | 1996 |